Sanofi

SNYNF

Held by 2 specialist biotech funds

2 funds opened new positions. Next phase3 readout (Glimepiride): Sep 2002.

Drug Manufacturers - GeneralCEO: Olivier CharmeilIPO: 2008Website ↗

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Catalysts

Phase 3Q3 2002GlimepirideDiabetes Mellitus, Non-Insulin-DependentNCT00044447

Primary: Change in HbA1C from baseline to Week 26.Enrollment:170/170Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2002Insulin glargineDiabetes Mellitus, Type 2NCT01336751

Primary: Change from baseline in hemoglobin A1c (HbA1c) levels at week 24 (24 weeks)Enrollment:212/212Sites: 1RANDOMIZED, TREATMENT

Phase 2Q1 2003Oxaliplatin, 5-FUHead and Neck CancerNCT00611754

Primary: To evaluate the efficacy of first line oxaliplatin in combination with 5-fluorouracil (5-FU) in patients with advanced inoperable or metastatic head and neck cancer.Enrollment:15/15Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Q1 2003Vasopressin V2 Receptor AntagonistChronic Heart FailureNCT00032747

Primary: Clinical status at day 120.Enrollment:338/338Sites: 9RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ1 2003ACAM1000SmallpoxNCT00053508

Primary: The proportion of subjects in each treatment group who develop a major cutaneous reaction on Day 7, Day 10, and/or Day 15. (Day 7, Day 10, and/or Day 15)Enrollment:274/274Sites: 3RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q3 2003GT160-246Clostridium Difficile-Associated Diarrhea, Clostridium Enterocolitis, Clostridium Difficile DiarrheaNCT00034294

Enrollment:Target 300Sites: 99RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2003Insulin GlargineDiabetes Mellitus, Type 2NCT00783744

Primary: Frequency of subjects with HbA1c ≤ 7.0 % and > 7.0 % (At endpoint)Enrollment:375/375Sites: 10RANDOMIZED, TREATMENT

Phase 2Q3 2003Human Anti-Transforming Growth Factor Beta-1 Monoclonal AntibodySystemic Sclerosis, SclerodermaNCT00043706

Sites: 4TREATMENT

Phase 3Q4 2003FexofenadineAsthmaNCT00044824

Primary: Change from baseline in Forced Expiratory Volume FEV1Enrollment:Target 1,000Sites: 7RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2004zolpidem-MR (modified release)Sleep Initiation and Maintenance DisordersNCT00630175

Primary: Polysommography (PSG) wake time after sleep onset (WASO)Enrollment:113/113Sites: 3RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2005oxaliplatin, 5 FUEndometrial CancerNCT00612495

Primary: Overall RR (World Health Organization [WHO]/Union Internationale Contre le Cancer [International Union Against Cancer] [UICC] criteria (during the study conduct)Enrollment:31/31Sites: 1RANDOMIZED, TREATMENT

Phase 2Q2 2005XRP0038 (NV1FGF)Peripheral Arterial DiseaseNCT00368797

Primary: Primary efficacy parameter: ulcer healing.Enrollment:125/125Sites: 6RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2005oxaliplatinColorectal CancerNCT00399750

Primary: To evaluate the safety and efficacy of three oxaliplatin-fluoropyrimidine regimens when combined with bevacizumab as therapy for previously untreated metastatic colorectal cancer (TREE 2)Enrollment:Target 373Sites: 1RANDOMIZED, TREATMENT

Phase 2Q2 2005DOCETAXELBreast NeoplasmsNCT00617968

Primary: Rate of clinical and radiological response evaluated according to RECIST criteria (During the study conduct)Enrollment:5/5Sites: 1RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2005G-CSF plus plerixaforMultiple Myeloma, Lymphoma, Non-Hodgkin'sNCT00395967

Primary: Number of Patients Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor 240 µg/kg and G-CSF for up to 3 Consecutive Days (approximately days 6-9)Enrollment:5/5Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3Q3 2005Enoxaparin sodiumPercutaneous Coronary InterventionNCT00077844

Primary: the composite of non-CABG major and minor bleeding (up to H48 after index PCI)Enrollment:Target 3,532RANDOMIZED, PREVENTION

Phase 3NegativeQ3 2005clopidogrel (SR25990C)Atrial Fibrillation, Vascular RiskNCT00243178

Primary: Primary outcome:time to the first occurrence of stroke, non-CNS systemic embolism, myocardial infarction or vascular death (during approximately three years of follow-up)Enrollment:6,706/6,706Sites: 32RANDOMIZED, PREVENTION

Phase 3Q4 2005SR34006 (idraparinux sodium) InjectionPulmonary Embolism, Deep Vein ThrombosisNCT00071279

Primary: Symptomatic recurrent PE/DVT during the 6-month study treatment period.Enrollment:1,215/1,215Sites: 65RANDOMIZED, DOUBLE

Phase 3Q1 2006ClopidogrelThrombosisNCT00716924

Primary: Incidence of post-percutaneous coronary intervention elevation of troponin T. (At 6 and 12 months post-PCI)Enrollment:155/155Sites: 1RANDOMIZED, TREATMENT

Phase 2Q1 2006Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)Meningitis, Meningococcal InfectionNCT00643916

Primary: Percentage of Participants With a ≥8 Antibody Titers as Measured by Serum Bactericidal Assay Human Complement (SBA-HC) After Each Vaccination. (Day 0 (baseline) and Day 28 post-Vaccinations 1 and 2)Enrollment:378/378Sites: 14NON_RANDOMIZED, PREVENTION

Phase 2Q2 2006rasburicase (SR29142)Nutritional and Metabolic DiseasesNCT00290992

Primary: Patients with a plasma uric acid level decreased to the endpoint by 48 hr after the start of first drug infusion and lasting until 24 hr after the start of final (Day 5) drug infusion.Enrollment:30/30Sites: 1TREATMENT

Phase 2Q2 2006CELIVARONE (SSR149744C)Atrial Fibrillation, Atrial FlutterNCT00232310

Primary: The primary efficacy endpoint is the rate of conversion to sinus rhythm documented by ECG just before the planned electrical cardioversion on D3 i.e. after 48 hours following the first study drug administration.Enrollment:150/150Sites: 9RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2006MyozymePompe Disease Late-Onset, Glycogen Storage Disease Type II GSD IINCT00765414

Primary: The objective of this extension study was to monitor the long-term safety and efficacy of a single patient (3 years)Enrollment:1/1Sites: 1NA, TREATMENT

Phase 2Q2 2006docetaxel and cisplatinHead and Neck NeoplasmsNCT00521521

Primary: Objective response rates (evaluated 8 weeks after the end of radiotherapy)Enrollment:86/86Sites: 1RANDOMIZED, TREATMENT

Phase 2Q2 2006Influenza virus vaccine (2004-2005 Formulation)InfluenzaNCT00858468

Primary: Percentage of Participants With Solicited Local and Systemic Reactions After Vaccination With Fluzone® 2004-2005 Pediatric Formulation. (Day 0 to Day 7 post-vaccination)Enrollment:394/394Sites: 8RANDOMIZED, PREVENTION

Phase 2Q3 2006SR31747AProstatic NeoplasmNCT00174863

Primary: Time To Clinical Progression assessed by every 4 weeks clinical examination and every 12 weeks radiological examinations (Thoraco-abdominopelvic CT scan ; Bone scan ± centered Bone X-rays, MRI)Enrollment:232/232Sites: 13RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ4 2006Granulocyte colony-stimulating factor plus plerixaforMultiple MyelomaNCT00103662

Primary: Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 2 or Fewer Days of Apheresis. (up to Day 6)Enrollment:302/302Sites: 39RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2007SODIUM DIVALPROATEBipolar DisorderNCT00271258

Primary: clinical examinationEnrollment:Target 200Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3Q1 2007SR58611AMajor Depressive DisorderNCT00252330

Primary: 17-item Hamilton Depression Rating Scale (HAM-D) total scoreEnrollment:476/476Sites: 2RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2007Facial WrinklesNCT00417469

Primary: To evaluate the pain experienced during and after the injection procedure for NADGL as compared to Captique® Injectable Gel in subjects undergoing cutaneous correction of nasolabial folds (NLFs).Enrollment:Target 45Sites: 1RANDOMIZED, SINGLE, TREATMENT

Phase 3NegativeQ2 2007triamcinolone acetonideRhinitisNCT00344942

Primary: Mean global score obtained on the basis of 5 evaluations : nasal obstruction, rhinorrhea, disturbed sense of smell, sneezing, facial heaviness. (7 days prior to each visit)Enrollment:77/77Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2007SR58611ADepressive DisorderNCT00319709

Primary: The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Depression Rating Scale (HAM-D) total score.Enrollment:288/288Sites: 5RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2007Hexadecasaccharide (SR123781A)Coronary AtherosclerosisNCT00123565

Primary: Efficacy: composite of all causes of death, new myocardial infarction, or severe myocardial ischemia requiring urgent repeat target vessel revascularization within 7 days following randomization.Enrollment:1,257/1,257Sites: 18RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ2 2007SR123781AVenous ThromboembolismNCT00338897

Primary: The primary efficacy endpoint is a composite of total venous thromboembolic events (VTE) including VTE related deaths during the treatment period.Enrollment:1,090/1,090Sites: 14RANDOMIZED, DOUBLE, PREVENTION

Phase 3Q3 2007insulin glulisineDiabetes Mellitus, Type 2NCT00135096

Primary: Compare change in weight from baseline to study week 52 in the per-protocol population of premeal Apidra vs postmeal Apidra, in patients receiving Lantus as basal insulin (52 weeks)Enrollment:345/345Sites: 1RANDOMIZED, TREATMENT

Phase 2Q3 2007Oxaliplatin (SR96669)Gastrointestinal CancerNCT00094965

Primary: Adverse events. (12 Cycles)Enrollment:43/43Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3Q4 2007alfuzosinProstatic HyperplasiaNCT00399464

Primary: Change in I-PSS (International Prostate Symptom Score) total score from baseline to endpoint (Day 84 or last available post-baseline assessment)Enrollment:1,177/1,177Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2007eplivanserin (SR46349)Sleep Initiation and Maintenance Disorders, InsomniaNCT00253903

Primary: Change from baseline of the mean pr-WASO (wake time after sleep onset using patient's sleep questionnaire) (at week 12)Enrollment:1,155/1,155Sites: 14RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2008SR58611AMajor Depressive DisorderNCT00432614

Primary: Change from baseline in Hamilton Depression Rating scale (HAM-D) total score (8 weeks)Enrollment:510/510Sites: 13RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2008SaredutantGeneralized AnxietyNCT00390533

Primary: Change from baseline to Day 56 of treatment in the Hamilton Anxiety Rating Scale (HAM-A) total score. (56 days)Enrollment:428/428Sites: 2RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2008saredutant (SR48968)Depressive DisorderNCT00415142

Primary: Change from baseline to Day 56 in the 17-item Hamilton Depression Rating Scale (HAM-D) total score. (Day 56)Enrollment:393/393Sites: 8RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2008larotaxel (XRP9881)Advanced Breast Cancer, Breast Cancer, Metastatic Breast CancerNCT00387907

Primary: Tumor response measured (every 2 cycles during treatment phase)Enrollment:6/6Sites: 1NA, TREATMENT

Phase 3Q2 2008DTaP-IPV combined vaccinePertussis, Diphtheria, PoliomyelitisNCT00319852

Primary: To provide information concerning the immunogenicity of Sanofi Pasteur's DTaP-IPV combined vaccine versus commercially available Biken's DTaP and Aventis Pasteur's IPV (IMOVAX POLIO) monovalent vaccines. (1 month post-vaccination)Enrollment:442/442Sites: 1RANDOMIZED, PREVENTION

Phase 2Q2 2008Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)Neoplasms, Cancer of the OvaryNCT00327171

Primary: Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by an Independent Review Committee (IRC) - Simon's Cohort (From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months))Enrollment:218/218Sites: 11RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2008Hepatitis A vaccine AVAXIM 80UHepatitis ANCT00483470

Primary: To provide information concerning the immunogenicity of AVAXIM 80U Pediatric vaccine (1 month post-vaccination)Enrollment:720/720Sites: 3RANDOMIZED, PREVENTION

Phase 3Q2 2008PEDIACEL® and Prevenar®Diphtheria, Tetanus, PertussisNCT00343421

Primary: To provide information concerning the immunogenicity of PEDIACEL® and Infanrix®-IPV+Hib (1 month post-vaccination)Enrollment:588/588Sites: 2RANDOMIZED, SINGLE, PREVENTION

Phase 2Q2 2008SSR150106Rheumatoid ArthritisNCT00545454

Primary: Change from baseline in mean C-Reactive Protein level (end of the 4-week double-blind treatment period)Enrollment:79/79Sites: 7RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ3 2008SSR180711CAlzheimer's DiseaseNCT00602680

Primary: Change in cognitive performance (4 weeks)Enrollment:1/1Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ3 2008docetaxelNon-small Cell Lung CancerNCT00378573

Primary: Progression Free Survival for Subjects With Locally Advanced or Metastatic (Stage IIIB or Stage IV) Non-Small Cell Lung Cancer (NSCLC) After Systemic Treatment With Gemcitabine, Docetaxel, and Bevacizumab as First Line Therapy (1 year post-registration)Enrollment:17/17Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3Q3 2008Poliomyelitis Vaccine inactivatedPoliomyelitis, PolioNCT00348387

Primary: To provide information concerning the immunogenicity of IMOVAX Polio™ vaccine (1 month post-vaccination 3)Enrollment:600/600Sites: 2RANDOMIZED, PREVENTION

Phase 3NegativeQ4 2008SatavaptanAscites, Liver CirrhosisNCT00359437

Primary: Number and time of recurrences of therapeutic paracenteses (up to 12 weeks)Enrollment:501/501Sites: 24RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2008Lactic AcidHygieneNCT00783640

Primary: The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale. (Throughout the study)Enrollment:27/27Sites: 1NON_RANDOMIZED, SUPPORTIVE_CARE

Phase 2Q4 2008IniparibPrimary Peritoneal Cancer, Advanced Epithelial Ovarian CancerNCT00677079

Primary: Best overall response (until treatment discontinuation (assessment at the at the end of each 8-week cycle))Enrollment:12/12Sites: 1NA, TREATMENT

Phase 2Q1 2009SSR180575Diabetic NeuropathiesNCT00502515

Primary: Rate of epidermal nerve fiber regeneration (24 weeks)Enrollment:309/309Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ1 2009Meningococcal polysaccharide diphtheria toxoid conjugateMeningitis, MeningococcemiaNCT00700713

Primary: Percentage of Participants With Serum Meningococcal Serogroups A, C, Y, and W-135 Bactericidal Antibody Titers ≥ 1:4 and ≥ 1:8 Before and Following Vaccination With Menactra® (Day 0 (pre-vaccination) and Day 30 post-vaccination)Enrollment:181/181Sites: 13NON_RANDOMIZED, PREVENTION

Phase 3Q1 2009eplivanserin (SR46349)Sleep Initiation and Maintenance DisordersNCT00679900

Primary: Sleepiness in the morning measured on a visual analog scale of the patient's sleep questionnaire (4 weeks)Enrollment:283/283Sites: 8RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2009TdcP-IPV vaccineDiphtheria, Tetanus, PertussisNCT00797511

Primary: Number of Participants With Seroprotection to Vaccine Antigens Following Vaccination With ADACEL Polio (TdcP-IPV) Vaccine. (Day 28 post-vaccination)Enrollment:132/132Sites: 1NA, PREVENTION

Phase 3NegativeQ2 2009AVE5530HypercholesterolemiaNCT00741715

Primary: Percent change from baseline in calculated LDL-C (At week 12)Enrollment:1,736/1,736Sites: 2RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ2 2009Japanese encephalitis vaccineJapanese Encephalitis, Hepatitis ANCT00735644

Primary: Number of Participants With Seroconversion to Vaccine Antigens Following Vaccination With JE-CV by GPO MBP Lots (Day 0 (pre-vaccination) and Day 28 post-vaccination)Enrollment:1,200/1,200Sites: 8RANDOMIZED, SINGLE, PREVENTION

Phase 2PositiveQ2 2009Polysaccharide Diphtheria Toxoid Conjugate VaccineMeningococcal Meningitis, Tetanus, DiphtheriaNCT00355121

Primary: Number of Participants With Antibodies Against Diphtheria and Tetanus at ≥ 1.0 IU/mL After DAPTACEL Vaccination (Day 30 post-vaccination (Visit 1))Enrollment:882/882Sites: 26RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2PositiveQ2 2009TeriflunomideMultiple SclerosisNCT00489489

Primary: Overview of Adverse Events [AE] (from first study drug intake up to 112 days after last intake or up to the first intake in the extension study LTS6047, whichever occured first (40 weeks max))Enrollment:118/118Sites: 5RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q2 2009Inactivated, split-virion influenza vaccineOrthomyxoviridae Infection, Influenza, Myxovirus InfectionNCT00383526

Primary: To provide information concerning the immunogenicity of Inactivated, Split-Virion Influenza vaccine (21 days post-vaccination)Enrollment:3,707/3,707Sites: 4RANDOMIZED, PREVENTION

Phase 3Q2 2009Semuloparin sodiumVenous ThromboembolismNCT00697099

Primary: Percentage of Participants Who Experienced Venous Thromboembolism Event [VTE] or Death From Any Cause (From randomization up to 10 days after surgery or the day of mandatory venography, whichever came first)Enrollment:2,326/2,326Sites: 30RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3Q3 2009LACTIC ACID(ND)HygieneNCT00932945

Primary: Evaluation of the absence of irritation and the good acceptability by using one specific scale which describes the intensity of the reaction. (From the treatment start up to the end of the study (treatment period 21 days))Enrollment:32/32Sites: 1NON_RANDOMIZED, PREVENTION

Phase 3Q3 2009LACTIC ACID(ND)HygieneNCT00933907

Primary: Evaluation of the absence of primary and accumulated dermical irritability and dermical sensitivity by using International Contact Dermatitis Research Group (ICDRG) scale. (From the treatment start to the end of the study( treatment period 6 weeks))Enrollment:55/55Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2009AVE1625SchizophreniaNCT00439634

Primary: Change from baseline in the MATRICS Cognitive Battery composite standardized score (at week 24)Enrollment:873/873Sites: 2RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ4 2009TeriflunomideMultiple SclerosisNCT00475865

Primary: Overview of Adverse Events (AE] (from first study drug intake up to 112 days after last intake or up to the first intake in the extension study LTS6047, whichever occured first (40 weeks max))Enrollment:123/123Sites: 6RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q4 2009REPEVAXHealthyNCT00928785

Primary: Anti-tetanus seroprotection rate (defined as the percentage of subjects with anti-tetanus antibody titre (ELISA) ≥ 0.1 IU/mL) (10 days)Enrollment:52/52Sites: 9RANDOMIZED, PREVENTION

Phase 3Q3 2010Semuloparin SodiumVenous ThromboembolismNCT00679588

Primary: Percentage of Participants Who Experience Venous Thromboembolism Event (VTE) or All-cause Death (From randomization up to 10 days after surgery or the day of mandatory venography, whichever comes first)Enrollment:4,413/4,413Sites: 270RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2NegativeQ4 2010Ferroquine (SSR97193)Plasmodium Falciparum InfectionNCT00988507

Primary: Recrudescent infections at D28 in the groups with ferroquine associated with artesunate. Recrudescence is defined as the recurrence of the same original strain of Plasmodium falciparum regardless of clinical symptoms (4 weeks)Enrollment:Target 440Sites: 10RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ1 2011IniparibBreast Cancer, MetastaticNCT01045304

Primary: Overall response rate (ORR) (Up the cut-off date for analysis defined as 16 weeks after the 1st dose in the last participant (maximum follow-up of 14 months))Enrollment:163/163Sites: 20RANDOMIZED, TREATMENT

Phase 2Q2 2011ALX-0081Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI), Stable Angina (Associated With High Risk PCI)NCT01020383

Primary: Incidence and severity of bleeding classified by the following criteria: TIMI major bleeding events, TIMI minor bleeding events, bleeding events requiring medical attention, defined as TIMI minimal bleeding events (30 days)Enrollment:364/364Sites: 39RANDOMIZED, TREATMENT

Phase 2Q3 20110.9% Normal SalineDiarrhea, Clostridium Difficile InfectionNCT00772343

Primary: Recurrence of Clostridium difficile infection. (Approximately 13 weeks after last injection)Enrollment:116/116Sites: 31RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q3 2011DTaP//PRP-T Combined VaccineDiphtheria, Tetanus, PertussisNCT01062477

Primary: Immunogenicity: To provide information concerning the immunogenicity of ACTACEL vaccine after primary and booster vaccination. (One month post-vaccination)Enrollment:1,056/1,056Sites: 2RANDOMIZED, PREVENTION

Phase 3Q4 2011insulin glargine (HOE901)Diabetes Mellitus, Non-Insulin-DependentNCT00069784

Primary: Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke (from randomization until study cut-off date (median duration of follow-up: 6.2 years))Enrollment:12,537/12,537Sites: 40RANDOMIZED, TREATMENT

Phase 2Q1 2012ombrabulin (AVE8062)Non-small Cell Lung CancerNCT01263886

Primary: Progression free survival (PFS) (approximately 1.5 years)Enrollment:176/176Sites: 43RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ3 2012Semuloparin sodiumThrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL)NCT01567904

Primary: Pharmacokinetics: Plasma concentrations of Semuloparin (6 samples; 0.5-1h and 6h after D4 injection, 1.5-4h and 12h after D5 injection, just before and 8h after D6 injection)Enrollment:2/2Sites: 1NON_RANDOMIZED, PREVENTION

Phase 3NegativeQ3 2012DocetaxelProstatic NeoplasmsNCT00514917

Primary: Median Progression-Free Survival (PFS) in Intent-to-treat (ITT) Population (Randomization until PSA progression or radiographic progression or death due to prostate cancer, assessed up to Month 60)Enrollment:413/413Sites: 9RANDOMIZED, TREATMENT

Phase 2Q4 2012paclitaxelBreast Cancer FemaleNCT01204125

Primary: Pathological Complete Response (pCR) rate defined as the complete absence of invasive carcinoma on histological examination of the breast at the time of definitive surgery and confirmed by blinded centralized review (at the time of definitive surgery)Enrollment:141/141Sites: 25RANDOMIZED, TREATMENT

Phase 2Q4 2012(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular PertussisPertussis, Tetanus, DiphtheriaNCT01689324

Primary: Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Following Vaccination With ADACEL® (Day 28 post-vaccination)Enrollment:43/43Sites: 3NA, PREVENTION

Phase 3PositiveQ3 2013AlirocumabHypercholesterolemiaNCT01644474

Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis (From Baseline to Week 24)Enrollment:103/103Sites: 8RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2013Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virusDengue, Dengue Fever, Dengue Hemorrhagic FeverNCT01488890

Primary: Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2 (Pre-injection 1, 28 days and 6 months post-injection 3)Enrollment:390/390Sites: 7RANDOMIZED, PREVENTION

Phase 3Q3 2014sevelamer carbonate 800mgRenal Failure ChronicNCT02332811

Primary: The reduction in serum phosphorus from baseline to end of study with Sevelamer carbonate tablets 800 mg and Sevelamer carbonate Powder 2.4 g in chronic kidney disease (CKD) patients both on haemodialysis and not on dialysis (up to 8 weeks)Enrollment:96/96Sites: 1RANDOMIZED, TREATMENT

Phase 3Q3 2014Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbedTetanus, Diphtheria, PertussisNCT02089347

Primary: Percentage of Participants With Diphtheria and Tetanus Post-vaccination Booster Response Following Vaccination With Either SP306 or DT (Day 28 post-vaccination)Enrollment:534/534Sites: 19RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3Q4 2014DoxorubicinBreast NeoplasmsNCT00021255

Primary: Percentage of Participants With Disease Free Survival at 5 Years (From randomization until relapse or death or up to 5 years)Enrollment:3,222/3,222Sites: 42RANDOMIZED, TREATMENT

Phase 3Q4 2014Lixisenatide (AVE0010)Type 2 DiabetesNCT01768559

Primary: Change in HbA1c From Baseline to Week 26 (Baseline, Week 26)Enrollment:894/894Sites: 199RANDOMIZED, TREATMENT

Phase 3NegativeQ1 2015SarilumabRheumatoid ArthritisNCT01764997

Primary: Change From Baseline in Disease Activity Score for 28 Joints - C-Reactive Protein (DAS28-CRP) Score at Week 24 (Baseline, Week 24)Enrollment:776/776Sites: 257RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2015HBVAXPRO 5µgVirus Diseases, Hepatitis BNCT02012998

Primary: Percentage of subjects with an anti-hepatitis B concentration ≥10 mIU/mL (One month after the challenge dose)Enrollment:751/751Sites: 10NA, PREVENTION

Phase 3Q1 2015Lixisenatide (AVE0010)Type 2 DiabetesNCT01798706

Primary: Absolute Change in HbA1c From Baseline to Week 24 (Baseline, Week 24)Enrollment:350/350Sites: 83RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2015SarilumabRheumatoid ArthritisNCT01709578

Primary: Percentage of Participants Who Achieved at Least 20% Improvement in the American College of Rheumatology (ACR20) Criteria at Week 24 (Week 24)Enrollment:546/546Sites: 196RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2015Agalsidase betaFabry DiseaseNCT00701415

Primary: Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium (Baseline, Week 52, Week 156 and Week 260)Enrollment:31/31Sites: 12RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2015LIXISENATIDE AVE0010Type II Diabetes MellitusNCT02274740

Primary: Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min) (After 10 weeks of treatment)Enrollment:2/2RANDOMIZED, TREATMENT

Phase 3Q2 2016Placebo (for Alirocumab)HypercholesterolemiaNCT02289963

Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis (From Baseline to Week 24)Enrollment:199/199Sites: 27RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2016CYD Dengue Vaccine (5-dose formulation)Dengue Fever, Dengue Hemorrhagic FeverNCT02623725

Primary: Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine Received in CYD13/CYD30: CYD Dengue Vaccine Booster Group (28 days post-dose 3 in CYD13 or CYD30 and 28 days post-booster injection in CYD64)Enrollment:251/251Sites: 5RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q1 2017Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1Tetanus, Diphtheria, PertussisNCT02587520

Primary: Number of Participants With Solicited Injections Site or Systemic Reactions Following Vaccination at Day 0: Aged 10-18 Years (Within 7 days after vaccination)Enrollment:1,363/1,363Sites: 20RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3PositiveQ2 2017AlirocumabHypercholesterolemiaNCT02584504

Primary: Percent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis (From Baseline to Week 12)Enrollment:163/163Sites: 30RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ4 2017SAR425899Type 2 Diabetes MellitusNCT02973321

Primary: Change From Baseline in HbA1c to Week 26 (Baseline, Week 26)Enrollment:296/296Sites: 59RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2018Dupilumab SAR231893 (REGN668)Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSw NP)NCT02898454

Primary: Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score (Baseline, Week 24)Enrollment:448/448Sites: 123RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2018ALX-0061Rheumatoid ArthritisNCT02518620

Primary: Number and Percentage of Subjects With American College of Rheumatology (ACR) 20 Response. (At Weeks 0, 12, 48, and 104)Enrollment:406/406Sites: 57NA, TREATMENT

Phase 2PositiveQ1 2019SAR156597Systemic SclerosisNCT02921971

Primary: Change From Baseline in Modified Rodnan Skin Score to Week 24 (Baseline, Week 24)Enrollment:97/97Sites: 44RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2019PlaceboOsteoarthritisNCT03190369

Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 Pain (Walking Pain) Subscale Score Over 26 Weeks (From Baseline up to Week 26)Enrollment:440/440Sites: 21RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2019PlaceboHyperphosphatemiaNCT03001011

Phase 2Q3 2019Avalglucosidase alfa (GZ402666)Glycogen Storage Disease Type II-Pompe's DiseaseNCT03019406

Primary: PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI) (From Baseline to Week 25)Enrollment:22/22Sites: 12RANDOMIZED, TREATMENT

Phase 2Q4 2019SAR440340Chronic Obstructive Pulmonary DiseaseNCT03546907

Primary: Annualized Rate of Moderate to Severe Acute Exacerbation Events in Chronic Obstructive Pulmonary Disease (AECOPD) Participants (From Baseline up to Week 52)Enrollment:343/343Sites: 83RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ4 2019Olipudase alfaSphingomyelin LipidosisNCT02292654

Phase 3PositiveQ1 2020DupilumabAtopic DermatitisNCT03912259

Primary: Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16 (Baseline, Week 16)Enrollment:165/165Sites: 27RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2020Alirocumab SAR236553 (REGN727)HypercholesterolemiaNCT03510715

Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis (Baseline to Week 12)Enrollment:18/18Sites: 10NA, TREATMENT

Phase 3Q3 2020Insulin Aspart SAR341402Type 1 Diabetes MellitusNCT03874715

Primary: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Measurable Timepoint (AUClast) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm) (0 hour (hr)(Pre-dose), 10, 20, 30, 40 & 50 minutes (min), 1hr, 1hr-10, 20, 30, 40 & 50min, 2hr, 2hr-15, 30 & 45min, 3hr, 3hr-15, 30 & 45min, 4hr, 4hr-20 & 40min, 5hr, 5hr-20 & 40min, 6hr, 6hr-30min, 7hr, 7hr-30min & 8hr post-dose on Day 112)Enrollment:210/210Sites: 33RANDOMIZED, TREATMENT

Phase 3NegativeQ3 2020Sarilumab SAR153191Corona Virus InfectionNCT04327388

Primary: Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points (Baseline to Day 29)Enrollment:420/420Sites: 47RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2020INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010Type 2 Diabetes MellitusNCT03767543

Primary: Change in glycated hemoglobin (HbA1c)% (Baseline to Week 26)Enrollment:265/265Sites: 32RANDOMIZED, TREATMENT

Phase 3Q1 2021Insulin glargine/Lixisenatide (HOE901/AVE0010)Type 2 Diabetes MellitusNCT03798054

Primary: Change in HbA1c (From Baseline to Week 24)Enrollment:878/878Sites: 79RANDOMIZED, TREATMENT

Phase 3Q1 2021placebo (saline)Sphingomyelin LipidosisNCT02004691

Primary: Percent Predicted (% Predicted) Hemoglobin (Hb) and Altitude-Adjusted Diffusing Capacity of the Lung for Carbon Monoxide (DLco) at Baseline (Baseline (Day 1))Enrollment:36/36Sites: 24RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2022isatuximab SAR650984Plasma Cell MyelomaNCT03275285

Phase 3PositiveQ1 2022FitusiranHemophiliaNCT03549871

Phase 3Q1 2022Dupilumab SAR231893 (REGN668)AsthmaNCT03620747

Phase 2Q2 2022Yellow fever vaccine (produced on serum-free Vero cells)Yellow FeverNCT05011123

Primary: Percentage of Yellow Fever-naive Participants Who Achieved Seroconversion 28 Days Post Dose 1 Enrolled in European Union (28 days post dose 1 (Day 29))Enrollment:690/690Sites: 23RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q2 2022Yellow fever vaccine (produced on serum-free Vero cells)Yellow Fever, Healthy VolunteersNCT04942210

Primary: Percentage of Yellow Fever (YF)-Naive Participants Who Achieved Seroconversion 28 Days Post Dose 1 (28 days post dose 1 (Day 29))Enrollment:568/568Sites: 11RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2NegativeQ3 2022Belumosudil (KD025)System; Sclerosis, Diffuse Cutaneous Systemic SclerosisNCT03919799

Phase 3NegativeQ4 2022AmcenestrantBreast CancerNCT05128773

Phase 2Q4 2022PRN473 (SAR444727)Atopic DermatitisNCT04992546

Phase 3Q1 2023Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate VaccineMeningococcal Immunisation, Healthy VolunteersNCT04936685

Primary: Group 1: Percentage of Participants With Sufficiency of Serum Bactericidal Assay Using Human Complement (hSBA) Vaccine Seroresponse at 30 Days Post Booster Dose (Baseline (Day 1) and 30 days after the MenACYW conjugate vaccine 5-year booster dose)Enrollment:209/209Sites: 26RANDOMIZED, PREVENTION

Phase 3Q1 2023FexofenadineSeasonal Allergic RhinitisNCT05692154

Phase 3Q1 2023Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)Healthy Volunteers (Meningococcal Infection)NCT03673462

Phase 3Q2 2023MenACYW conjugate vaccineMeningococcal InfectionsNCT03547271

Phase 2NegativeQ2 2023Isatuximab SAR650984Warm Autoimmune Hemolytic Anemia (w AIHA)NCT04661033

Phase 2NegativeQ3 2023PembrolizumabSquamous Cell Carcinoma of Head and NeckNCT05061420

Phase 2Q3 2023THOR-707Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular CarcinomaNCT05104567

Phase 2Q3 2023Pneumococcal Conjugate Vaccine formulation 1Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus ImmunisationNCT04398706

Phase 3NegativeQ4 2023Recombinant influenza vaccine (RIV4)Influenza ImmunizationNCT05513391

Phase 2NegativeQ1 2024SAR443820Amyotrophic Lateral SclerosisNCT05237284

Phase 3Q3 2024DupilumabChronic Rhinosinusitis With Nasal PolypsNCT05878093

Phase 3Q4 2024DupilumabChronic Spontaneous UrticariaNCT05526521

Phase 2NegativeQ4 2024SAR443820Multiple SclerosisNCT05630547

Phase 2NegativeQ1 2025SAR442501OsteochondrodysplasiaNCT06067425

Phase 3NegativeQ2 2025Doxercalciferol (GZ427397)Secondary Hyperparathyroidism-Chronic Kidney DiseaseNCT02859896

Phase 3NegativeQ2 2025Low Dose (LD) RSVt vaccineRSV ImmunisationNCT06705140

Phase 3Q3 2025AmlitelimabDermatitis AtopicNCT06130566

Phase 2Q3 2025AmlitelimabAlopecia AreataNCT06444451

Phase 3Q4 2025Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate VaccineMeningococcal Immunisation, Healthy VolunteersNCT05794230

Phase 2NegativeQ4 2025THOR-707MetastasisNCT04009681

Phase 2Q4 2025IsatuximabRelapsed/Refractory Multiple MyelomaNCT05704049

Phase 3Q1 2026Erectile DysfunctionNCT06805513

Phase 3Q2 2026MenACYW conjugate vaccineMeningococcal Infection, Healthy VolunteersNCT07135986

Phase 2Q2 2026DupilumabColitis UlcerativeNCT05731128

Phase 3Q2 2026Venglustat (GZ402671)Fabry DiseaseNCT05280548

Phase 3Q2 2026DupilumabLichen Simplex ChronicusNCT06687967

Phase 3Q2 2026AmlitelimabDermatitis AtopicNCT06407934

Phase 2Q3 2026SAR441344 IVSystemic Lupus ErythematosusNCT05039840

Phase 2Q3 2026AmlitelimabCoeliac Disease, Celiac DiseaseNCT06557772

Phase 3Q3 2026Yellow fever vaccine (live)Yellow Fever ImmunizationNCT07103148

Phase 3Q3 2026FitusiranHemophiliaNCT03974113

Phase 2Q3 2026BelumosudilChronic Graft Versus Host DiseaseNCT05567406

Phase 2Q3 2026AmlitelimabAsthmaNCT06033833

Phase 3Q4 2026FitusiranHemophiliaNCT03754790

Phase 3Q4 2026rilzabrutinibImmune ThrombocytopeniaNCT07216079

Phase 3Q4 2026PCV21Pneumococcal InfectionsNCT06838000

Phase 3Q1 2027PCV21Sickle Cell DiseaseNCT07247188

Phase 3Q1 2027Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal PolypsNCT06834360

Phase 3Q1 2027Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal PolypsNCT06834347

Phase 3Q1 2027efanesoctocog alfa (BIVV001)Hemophilia ANCT04644575

Phase 2Q1 2027SAR445877Solid TumorNCT05584670

Phase 2Q1 2027SAR445419Allogenic Stem Cell TransplantationNCT05726682

Phase 3Q1 2027FitusiranHemophiliaNCT05662319

Phase 3Q2 2027Isatuximab SAR650984Plasma Cell MyelomaNCT03319667

Phase 2Q2 2027SAR444336Microscopic ColitisNCT07156175

Phase 2Q2 2027FrexalimabType 1 Diabetes MellitusNCT06111586

Phase 2Q2 2027Pentavalent Meningococcal ABCYW vaccineMeningococcal Immunization, Healthy VolunteersNCT06647407

Phase 2Q2 2027SAR402663Neovascular Age-related Macular DegenerationNCT06660667

Phase 3Q2 2027DupilumabPruritusNCT05263206

Phase 2Q3 2027SAR441566Crohn's DiseaseNCT06637631

Phase 2Q3 2027SAR441566Colitis UlcerativeNCT06867094

Phase 2Q3 2027BrivekimigHidradenitis SuppurativaNCT07170917

Phase 3Q3 2027PCV21 vaccinePneumococcal ImmunizationNCT06824181

Phase 2Q3 2027SAR445399Hidradenitis SuppurativaNCT07225569

Phase 2Q4 2027SAR446597Geographic AtrophyNCT07215234

Phase 3Q4 2027Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal PolypsNCT07484230

Phase 3Q4 2027PCV21 vaccinePneumococcal ImmunizationNCT06824194

Phase 3Q4 2027DupilumabPrurigo NodularisNCT06293053

Phase 2Q4 2027SAR445399Non-cystic Fibrosis BronchiectasisNCT07547436

Phase 3Q4 2027rilzabrutinibImmune ThrombocytopeniaNCT07007962

Phase 2Q1 2028TeplizumabType 1 Diabetes MellitusNCT06791291

Phase 3Q1 2028FrexalimabMultiple SclerosisNCT06141486

Phase 3Q2 2028DuvakitugUlcerative ColitisNCT07184996

Phase 3Q2 2028TeplizumabType 1 Diabetes MellitusNCT07088068

Phase 3Q2 2028RilzabrutinibImmunoglobulin G4 Related DiseaseNCT07190196

Phase 2Q2 2028SAR447537Alpha 1-Antitrypsin Deficiency, EmphysemaNCT05897424

Phase 3Q3 2028DuvakitugUlcerative ColitisNCT07185009

Phase 2Q3 2028BelumosudilChronic Graft Versus Host DiseaseNCT07116031

Phase 3Q3 2028BelumosudilChronic Graft Versus Host DiseaseNCT06143891

Phase 2Q4 2028Acne mRNA vaccineAcneNCT06316297

Phase 3Q4 2028Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal PolypsNCT07424144

Phase 3Q4 2028DupilumabWheezing, AsthmaNCT06191315

Phase 3Q1 2029AmlitelimabDermatitis AtopicNCT05492578

Phase 3Q1 2029BelumosudilLung Transplant RejectionNCT06082037

Phase 2Q1 2029SAR446268Myotonic DystrophyNCT06844214

Phase 2Q2 2029Acne mRNA vaccineAcneNCT07013747

Phase 3Q4 2029LunsekimigChronic Obstructive Pulmonary DiseaseNCT07190209

Phase 3Q4 2029LunsekimigChronic Obstructive Pulmonary DiseaseNCT07190222

Phase 2Q2 2030balinatunfibColitis Ulcerative, Crohn's DiseaseNCT07222189

Phase 2Q2 2031AmlitelimabDermatitis AtopicNCT05769777

Phase 2Q2 2031Blood draw for the laboratory assessmentUsher's SyndromeNCT02065011

Phase 2Q3 2033Long term follow up in all patients who received SAR422459 in previous study TDU13583Stargardt's DiseaseNCT01736592

Phase 3TBDinsulin glulisineDiabetes Mellitus, Type 1NCT00290979

Primary: Non-inferiority in the efficacy and safety of HMR1964 as compared with Insulin lisproEnrollment:Target 250Sites: 1RANDOMIZED, TREATMENT

Phase 2TBDAMD3100Acute Myelogenous Leukemia, Myelodysplastic SyndromesNCT00396968

Primary: To determine if AMD3100 given in a sequential dose escalation at 80, 160 and 240 µg/kg in combination with busulfan, fludarabine (and ATG for unrelated or HLA nonidentical donors) for treatment of AML/MDS:0NON_RANDOMIZED, TREATMENT

Phase 3TBDEnoxaparin sodiumArthroplasty, Replacement, HipNCT00349180

Primary: Incidence of VTEEnrollment:Target 156Sites: 1RANDOMIZED, DOUBLE, PREVENTION

Sanofi

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Catalysts

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research